TY  - JOUR
A1  - Johnson, Michael D.
A1  - Akiyama, Kazunori
A1  - Blackburn, Lindy
A1  - Bouman, Katherine L.
A1  - Broderick, Avery E.
A1  - Cardoso, Vitor
A1  - Fender, Rob P.
A1  - Fromm, Christian M.
A1  - Galison, Peter
A1  - Gómez, José L.
A1  - Haggard, Daryl
A1  - Lister, Matthew L.
A1  - Lobanov, Andrei P.
A1  - Markoff, Sera
A1  - Narayan, Ramesh
A1  - Natarajan, Priyamvada
A1  - Nichols, Tiffany
A1  - Pesce, Dominic W.
A1  - Younsi, Ziri
A1  - Chael, Andrew
A1  - Chatterjee, Koushik
A1  - Chaves, Ryan
A1  - Doboszewski, Juliusz
A1  - Dodson, Richard
A1  - Doeleman, Sheperd S.
A1  - Elder, Jamee
A1  - Fitzpatrick, Garret
A1  - Haworth, Kari
A1  - Houston, Janice
A1  - Issaoun, Sara
A1  - Kovalev, Yuri Y.
A1  - Levis, Aviad
A1  - Lico, Rocco
A1  - Marcoci, Alexandru
A1  - Martens, Niels C. M.
A1  - Nagar, Neil M.
A1  - Oppenheimer, Aaron
A1  - Palumbo, Daniel C. M.
A1  - Ricarte, Angelo
A1  - Rioja, María  J.
A1  - Roelofs, Freek
A1  - Thresher, Ann C.
A1  - Tiede, Paul
A1  - Weintroub, Jonathan
A1  - Wielgus, Maciek
T1  - Key science goals for the next-generation Event Horizon Telescope
JF  - Galaxies
N2  - The Event Horizon Telescope (EHT) has led to the first images of a supermassive black hole, revealing the central compact objects in the elliptical galaxy M87 and the Milky Way. Proposed upgrades to this array through the next-generation EHT (ngEHT) program would sharply improve the angular resolution, dynamic range, and temporal coverage of the existing EHT observations. These improvements will uniquely enable a wealth of transformative new discoveries related to black hole science, extending from event-horizon-scale studies of strong gravity to studies of explosive transients to the cosmological growth and influence of supermassive black holes. Here, we present the key science goals for the ngEHT and their associated instrument requirements, both of which have been formulated through a multi-year international effort involving hundreds of scientists worldwide.
KW  - black holes
KW  - general relativity
KW  - interferometry
KW  - accretion
KW  - relativistic jets
KW  - very-long-baseline interferometry
KW  - EHT
KW  - ngEHT
Y1  - 2023
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-313525
SN  - 2075-4434
VL  - 11
IS  - 3
ER  - 
TY  - JOUR
A1  - Leich, E.
A1  - Weißbach, S.
A1  - Klein, H.-U.
A1  - Grieb, T.
A1  - Pischimarov, J.
A1  - Stühmer, T.
A1  - Chatterjee, M.
A1  - Steinbrunn, T.
A1  - Langer, C.
A1  - Eilers, M.
A1  - Knop, S.
A1  - Einsele, H.
A1  - Bargou, R.
A1  - Rosenwald, A.
T1  - Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules
JF  - Blood Cancer Journal
N2  - Multiple myeloma (MM) is a largely incurable plasma cell malignancy with a poorly understood and heterogeneous clinical course. To identify potential, functionally relevant somatic mutations in MM, we performed whole-exome sequencing of five primary MM, corresponding germline DNA and six MM cell lines, and developed a bioinformatics strategy that also integrated published mutational data of 38 MM patients. Our analysis confirms that identical, recurrent mutations of single genes are infrequent in MM, but highlights that mutations cluster in important cellular pathways. Specifically, we show enrichment of mutations in adhesion molecules of MM cells, emphasizing the important role for the interaction of the MM cells with their microenvironment. We describe an increased rate of mutations in receptor tyrosine kinases (RTKs) and associated signaling effectors, for example, in EGFR, ERBB3, KRAS and MAP2K2, pointing to a role of aberrant RTK signaling in the development or progression of MM. The diversity of mutations affecting different nodes of a particular signaling network appears to be an intrinsic feature of individual MM samples, and the elucidation of intra- as well as interindividual redundancy in mutations that affect survival pathways will help to better tailor targeted therapeutic strategies to the specific needs of the MM patient.
KW  - multiple myeloma
KW  - somatic mutations
KW  - whole-exome sequencing
KW  - adhesion
KW  - receptor tyrosine kinases
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-128663
VL  - 3
IS  - e102
ER  - 
TY  - JOUR
A1  - Boulos, Joelle C.
A1  - Saeed, Mohamed E. M.
A1  - Chatterjee, Manik
A1  - Bülbül, Yagmur
A1  - Crudo, Francesco
A1  - Marko, Doris
A1  - Munder, Markus
A1  - Klauck, Sabine M.
A1  - Efferth, Thomas
T1  - Repurposing of the ALK inhibitor crizotinib for acute leukemia and multiple myeloma cells
JF  - Pharmaceuticals
N2  - Crizotinib was a first generation of ALK tyrosine kinase inhibitor approved for the treatment of ALK-positive non-small-cell lung carcinoma (NSCLC) patients. COMPARE and cluster analyses of transcriptomic data of the NCI cell line panel indicated that genes with different cellular functions regulated the sensitivity or resistance of cancer cells to crizotinib. Transcription factor binding motif analyses in gene promoters divulged two transcription factors possibly regulating the expression of these genes, i.e., RXRA and GATA1, which are important for leukemia and erythroid development, respectively. COMPARE analyses also implied that cell lines of various cancer types displayed varying degrees of sensitivity to crizotinib. Unexpectedly, leukemia but not lung cancer cells were the most sensitive cells among the different types of NCI cancer cell lines. Re-examining this result in another panel of cell lines indeed revealed that crizotinib exhibited potent cytotoxicity towards acute myeloid leukemia and multiple myeloma cells. P-glycoprotein-overexpressing CEM/ADR5000 leukemia cells were cross-resistant to crizotinib. NCI-H929 multiple myeloma cells were the most sensitive cells. Hence, we evaluated the mode of action of crizotinib on these cells. Although crizotinib is a TKI, it showed highest correlation rates with DNA topoisomerase II inhibitors and tubulin inhibitors. The altered gene expression profiles after crizotinib treatment predicted several networks, where TOP2A and genes related to cell cycle were downregulated. Cell cycle analyses showed that cells incubated with crizotinib for 24 h accumulated in the G\(_2\)M phase. Crizotinib also increased the number of p-H3(Ser10)-positive NCI-H929 cells illustrating crizotinib's ability to prevent mitotic exit. However, cells accumulated in the sub-G\(_0\)G\(_1\) fraction with longer incubation periods, indicating apoptosis induction. Additionally, crizotinib disassembled the tubulin network of U2OS cells expressing an α-tubulin-GFP fusion protein, preventing migration of cancer cells. This result was verified by in vitro tubulin polymerization assays. In silico molecular docking also revealed a strong binding affinity of crizotinib to the colchicine and Vinca alkaloid binding sites. Taken together, these results demonstrate that crizotinib destabilized microtubules. Additionally, the decatenation assay showed that crizotinib partwise inhibited the catalytic activity of DNA topoisomerase II. In conclusion, crizotinib exerted kinase-independent cytotoxic effects through the dual inhibition of tubulin polymerization and topoisomerase II and might be used to treat not only NSCLC but also multiple myeloma.
KW  - acute myeloid leukemia
KW  - drug repurposing
KW  - multiple myeloma
KW  - network pharmacology
KW  - transcriptomics
KW  - tyrosine kinase inhibitors
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-250258
SN  - 1424-8247
VL  - 14
IS  - 11
ER  -